Opinion: Biopharma innovation needs to harness lessons learned from Covid-19
The pandemic is a prime case study of what can be accomplished when science delivers. The pharmaceutical and biotech industry harnessed new technologies, collaborated in new ways, and worked at an accelerated pace to help prevent infections with SARS-CoV-2, the virus that causes Covid-19, and treat those who got the disease.
Applying these new ways of working will revolutionize the understanding and treatment of diseases with no available therapies.
